GlassScriptPhysician profile
Mark F Indzonka
NPI 1912911405
$11,749.64
in general payments reported to CMS, 2019-2025
32 companies · $1,599 in 2025
The $1,599 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,097 · 2020: $1,627 · 2021: $2,197 · 2022: $1,564 · 2023: $1,628 · 2024: $1,037 · 2025: $1,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,264.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,640.00 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $1,332.17 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $1,148.73 | 2019-2025 | Brilinta, Farxiga |
| Pfizer INC. | $1,125.96 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,033.26 | 2019-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $830.57 | 2021-2025 | Verquvo, Capvaxive |
| Novartis Pharmaceuticals Corporation | $818.97 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $802.17 | 2019-2025 | Jardiance |
| Esperion Therapeutics, INC. | $496.24 | 2020-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $463.63 | 2019-2024 | |
| Boston Scientific Corporation | $299.88 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Watchman Access System, Watchman Flx |
| Scpharmaceuticals INC. | $293.62 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $231.82 | 2020-2025 | Onpattro |
| Arbor Pharmaceuticals, INC. | $229.08 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $214.75 | 2019-2023 | Lifevest |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $160.45 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $106.20 | 2023-2025 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $87.08 | 2025 | |
| Amarin Pharma, INC. | $83.60 | 2019-2021 | |
| Inspire Medical Systems, INC. | $67.09 | 2024-2025 | Inspire |
| Kiniksa Pharmaceuticals, LTD. | $54.02 | 2022-2023 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $50.27 | 2019-2021 | |
| Abbott Laboratories | $28.79 | 2021-2024 | Jot Dx |
| Kiniksa Pharmaceuticals International, Plc | $18.64 | 2024 | Arcalyst |
| Azurity Pharmaceuticals, INC. | $18.29 | 2023 | Edarbi |
| Baxter Healthcare | $17.69 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Amicus Therapeutics, INC. | $17.62 | 2019 | |
| G Medical Diagnostic Services, INC. | $16.90 | 2024 | Cardiac Monitoring Suite |
| Medtronic, INC. | $16.07 | 2022 | |
| Astellas Pharma US INC | $16.00 | 2019 | |
| Novo Nordisk INC | $15.80 | 2023 | Ozempic, Rybelsus |
| Braemar Manufacturing, LLC | $14.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Indzonka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.